SOST and osteogenesis imperfecta: Pharmacologically,GalNAc-Apc001 exhibited superior therapeutic efficacy by mitigatingthe suppressive effects of sclerostin on Wnt signaling, upregulatingbone formation markers, and enhancing bone mass in a Col1a2+/G610C osteogenesis imperfecta mousemodel.